Does sacubitril/valsartan improve systemic right ventricle remodeling, systolic function, and clinical status in patients with a failing systemic right ventricle?
Sacubitril/valsartan appears safe and effective for improving ventricular remodeling and clinical status in patients with a failing systemic right ventricle.
Our data showed that sacubitril/valsartan is well tolerated and is associated with systemic right ventricle remodeling and improved systolic function as well as improved clinical status, supporting its use in this complex population.
Fusco et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: